| MGMT Status | Total (n = 20) | |
Methylated (n = 12) | Unmethylated (n = 8) | ||
Nil response | 1 (8.3%) | 1 (12.5%) | 2 (10%) |
Yes | 11 (91.7%) | 7 (87.5%) | 18 (90%) |
TMZ with RT ® adj TMZ * 1 year | 5 (41.7%) | 2 (25%) | 7 (35%) |
Irinotecan+ bevacizumab | 1 (8.3%) | 5 (62.5%) | 6 (30%) |
Bevacizumab alone | 2 (16.7%) | 0 (0%) | 2 (10%) |
Lost follow up | 2 (16.7%) | 0 (0%) | 2 (10%) |
SRS | 1 (8.3%) | 0 (0%) | 1 (5%) |